Bacterial pneumonia
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- Acute infection of the lung parenchyma caused by bacteria (e.g., Streptococcus pneumoniae, Haemophilus influenzae, Chlamydia pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila). Signs and symptoms include productive cough, fever, chills, shortness of breath, and chest pain.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Bacterial pneumonia
- Therapeutic area
- Infectious Disease
- bacterial pneumonia
- Bacteria caused pneumonia
- Bacteria pneumonia
- pneumonia due to other gram-negative bacteria
- Severity
- Severe
- Acquired
- Inflammatory
- Infectious Disease
- Pulmonology
- MONDO ID
- MONDO:0004652
- Parent condition
- MONDO:0005113
Related records
Broader conditions (15)
- Bacterial infectious disease
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
- Inflammatory disease
- Lower respiratory tract disorder
- Lung disorder
- Pneumonia
- Pneumonitis
- Respiratory system disorder
- Respiratory tract infectious disorder
Narrower conditions (11)
- Anaerobic pneumonia
- Klebsiella pneumonia
- Legionnaires' disease
- Mycoplasma pneumoniae pneumonia
- Pneumonia caused by chlamydia
- Pneumonia caused by gram negative bacteria
- Pneumonia caused by pseudomonas aeruginosa infection
- Rickettsial pneumonia
- Staphylococcal pneumonia
- Staphylococcus aureus pneumonia
- Streptococcal pneumonia
Trials (134)
- " Study of the Benefit of Nebulized Amikacin in the Treatment of Gram-negative Bacillus Pneumonia Acquired During Mechanical Ventilation in Patients Receiving Extracorporeal Membrane Veno-arterial Oxygenation "
- A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101
- A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants
- A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia
- A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection
- A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
- A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia
- A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine
- A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization
- A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections
- A Study of the Safety and Effectiveness of Levofloxacin Compared With Ceftriaxone Sodium or Cefuroxime Axetil in the Treatment of Adults With Pneumonia
- A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
- A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia
- A Study to Compare the Efficacy and Safety of Levofloxacin in the Treatment of Children With Community-acquired Pneumonia in the Hospital or Outpatient Setting
- A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients
- A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine
- A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age
- A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age
- A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose
- Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative and / or Gram-positive Bacterial Colonization
Approved drugs (8)
- Cefiderocol sulfate tosylate
- Ceftaroline fosamil acetate
- Doripenem monohydrate
- Ertapenem sodium
- Lefamulin acetate
- Omadacycline tosylate
- Telavancin hydrochloride
- Telithromycin
Drugs in development (37)
- Acorafloxacin hydrochloride Phase 2
- Amikacin Phase 3
- Amikacin sulfate Phase 2
- Amoxicillin Phase 2
- Ampicillin sodium Phase 3
- Arbekacin Phase 1
- Cefiderocol Phase 1
- Ceftaroline Phase 3
- Ceftaroline fosamil Phase 3
- Ceftriaxone Phase 3
- Cilastatin Phase 3
- Clarithromycin Phase 3
- Clavulanic acid Phase 2
- Colistin Phase 3
- Daptomycin Phase 3
- Delafloxacin Phase 3
- Fosfomycin Phase 2
- Gentamicin sulfate Phase 2
- Imipenem Phase 3
- Levofloxacin Phase 3
Other linked drugs (2)
- Avibactam
- Ceftazidime